the world’s first dual chamber leadless pacemaker system. The AVEIR DR from Abott was approved by the U.S. Food and Drug Administration in June 2023 to help patients with slow or abnormal heart ...

Abbott Laboratories recently announced promising results from its AVEIR Conduction System Pacing study, showcasing its innovative leadless pacemaker technology. Over the last quarter, the company ...

The present device has not yet been FDA approved, but Abbott announced in December ... implant of a de novo single-chamber or dual-chamber leadless pacemaker. The primary safety endpoint was ...

All study participants received the AVEIR ventricular (VR) leadless pacemaker at the end of the procedure. Abbott said that, to maximize potential benefits to patients, the company is developing ...

Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has ...

Abbott Laboratories recently announced promising results from its AVEIR Conduction System Pacing study, showcasing its innovative leadless pacemaker technology. Over the last quarter, the company's ...

Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has ...

Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also ...